

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 23D2065421	(X3) Date Survey Completed 02/05/2020
Name of Provider or Supplier Comprehensive Pain Solutions, Pllc	Street Address, City, State 37459 Schoolcraft Road, Livonia, MI	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2009	<p>TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(1)</p> <p>The individual testing or examining the samples and the laboratory director must attest to the routine integration of the samples into the patient workload using the laboratory's routine methods.</p> <p>This STANDARD is not met as evidenced by: . Based on record review and interview with the Laboratory Director (LD), the individual testing proficiency testing samples failed to attest to the routine integration of samples into the patient workload for 1 (UT-B 2018) of 6 testing events reviewed. Findings include: 1. A review of the laboratory's College of American Pathologists' (CAP) proficiency testing records revealed a lack of attestation from a previously employed testing personnel performing proficiency testing for the 2018 UT-B event. 2. An interview on 2/5/2020 at 10:40 am with the LD confirmed the previously employed testing personnel did not attest to the integration of samples into the patient workload.</p>
D5217	<p>EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(c)(1)</p> <p>At least twice annually, the laboratory must verify the accuracy of any test or procedure it performs that is not included in subpart I of this part.</p> <p>This STANDARD is not met as evidenced by: . Based on record review and interview with the Laboratory Director (LD), the laboratory failed to verify the accuracy of toxicology testing at least twice annually for 1 (2018) of 2 years reviewed. Findings include: 1. A review of the laboratory's "Peer Comparison Data and Target Comparison Data" revealed a lack of</p>

documentation of twice annual verification of accuracy for the second testing event for the following analytes: a. 2-OH-ethylflurazepam b. Secobarbital c. MDEA d. Tapentadol 2. An interview on 2/5/2020 at 10:47 am with the LD confirmed twice annual verification of accuracy testing was not performed for the second event in 2018 for the analytes listed above.